[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
May 18, 2011

Diabetes Quality Measures

JAMA. 2011;305(19):1966-1968. doi:10.1001/jama.2011.642

To the Editor: Drs Pogach and Aron1 used the Toyota example of failure to quickly “pull the cord” at the first sign of a safety or quality problem to suggest leading guideline and measure development organizations did not respond to changing evidence on control of glycated hemoglobin (HbA1c) levels in patients with diabetes. In fact, the National Committee for Quality Assurance (NCQA) did respond quickly when the National Institutes of Health suspended the ACCORD (Action to Control Cardiovascular Risk in Diabetes) study2 intervention group in February 2008 and the ACCORD and ADVANCE3 (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) studies were published later that year.

First Page Preview View Large
First page PDF preview
First page PDF preview
×